54 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
From carbohydrates to drug-like fragments: Rational development of novela-amylase inhibitors.
Freie Universit£T Berlin
Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors.
Chengdu University of Tcm
Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.
Sloan-Kettering Institute For Cancer Research
Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.
Tufts University
Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.
Nerviano Medical Sciences
Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors.
Montclair State University
Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors.
University of Geneva
Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
China Pharmaceutical University
Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.
Vertex Pharmaceuticals
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).
Exelixis
Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
Seoul National University
Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.
Astrazeneca
Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.
Vernalis
Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90.
Merck Serono
Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90.
Serenex
Discovery and development of heat shock protein 90 inhibitors.
Memorial Sloan-Kettering Cancer Center
Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.
University of Ferrara
A small molecule that preferentially binds the closed conformation of Hsp90.
San Diego State University
Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
Sanofi-Aventis Research and Development
Lead identification ofß-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.
Trinity College
Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.
Trinity College
Synthesis and Validation of the First Cell-Impermeable Hsp90α-Selective Inhibitors.
The University of Notre Dame
Structure-Activity Relationship Study of Tertiary Alcohol Hsp90α-Selective Inhibitors with Novel Binding Mode.
The University of Notre Dame
Recent advances toward the development of Hsp90 C-terminal inhibitors.
University of Notre Dame
The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.
Aligarh Muslim University
Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.
Shandong University
Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
Memorial Sloan-Kettering Cancer Center
Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.
Taiho Pharmaceutical
Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach.
Sun Yat-Sen University
The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with
The University of Notre Dame
Synthesis and Structure-Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90.
University of New South Wales
Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles.
University of Geneva
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
China Pharmaceutical University
Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
China Pharmaceutical University
Heat shock protein 70 inhibitors. 1. 2,5'-thiodipyrimidine and 5-(phenylthio)pyrimidine acrylamides as irreversible binders to an allosteric site on heat shock protein 70.
Memorial Sloan-Kettering Cancer Center
Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells.
University of California
Dimeric and trimeric triazole based molecules as a new class of Hsp90 molecular chaperone inhibitors.
University of Salerno
1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
Chong Kun Dang Pharmaceutical
Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity
Emerald Health Pharmaceuticals
Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
Merck Sharp & Dohme
Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
Bayer Pharma Aktiengesellschaft
Targeting NAD biosynthesis in bacterial pathogens: Structure-based development of inhibitors of nicotinate mononucleotide adenylyltransferase NadD.
Burnham Institute For Medical Research
N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.
Glaxosmithkline
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
University of Newcastle